275 related articles for article (PubMed ID: 9447815)
41. Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia.
Ottema S; Mulet-Lazaro R; Beverloo HB; Erpelinck C; van Herk S; van der Helm R; Havermans M; Grob T; Valk PJM; Bindels E; Haferlach T; Haferlach C; Smeenk L; Delwel R
Blood; 2020 Jul; 136(2):224-234. PubMed ID: 32219447
[TBL] [Abstract][Full Text] [Related]
42. Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia.
Cuenco GM; Ren R
Oncogene; 2001 Dec; 20(57):8236-48. PubMed ID: 11781838
[TBL] [Abstract][Full Text] [Related]
43. The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions.
Wieser R
Gene; 2007 Jul; 396(2):346-57. PubMed ID: 17507183
[TBL] [Abstract][Full Text] [Related]
44. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.
Gröschel S; Schlenk RF; Engelmann J; Rockova V; Teleanu V; Kühn MW; Eiwen K; Erpelinck C; Havermans M; Lübbert M; Germing U; Schmidt-Wolf IG; Beverloo HB; Schuurhuis GJ; Ossenkoppele GJ; Schlegelberger B; Verdonck LF; Vellenga E; Verhoef G; Vandenberghe P; Pabst T; Bargetzi M; Krauter J; Ganser A; Valk PJ; Löwenberg B; Döhner K; Döhner H; Delwel R
J Clin Oncol; 2013 Jan; 31(1):95-103. PubMed ID: 23008312
[TBL] [Abstract][Full Text] [Related]
45. Leukemogenesis by CBF oncoproteins.
Friedman AD
Leukemia; 1999 Dec; 13(12):1932-42. PubMed ID: 10602413
[TBL] [Abstract][Full Text] [Related]
46. The role of EVI1 in normal and leukemic cells.
Buonamici S; Chakraborty S; Senyuk V; Nucifora G
Blood Cells Mol Dis; 2003; 31(2):206-12. PubMed ID: 12972028
[TBL] [Abstract][Full Text] [Related]
47. Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases.
Haferlach C; Bacher U; Grossmann V; Schindela S; Zenger M; Kohlmann A; Kern W; Haferlach T; Schnittger S
Genes Chromosomes Cancer; 2012 Dec; 51(12):1079-85. PubMed ID: 22887804
[TBL] [Abstract][Full Text] [Related]
48. The EVI-1 gene--its role in pathogenesis of human leukemias.
Jółkowska J; Witt M
Leuk Res; 2000 Jul; 24(7):553-8. PubMed ID: 10867128
[TBL] [Abstract][Full Text] [Related]
49. Amplification and translocation of 3q26 with overexpression of EVI1 in Fanconi anemia-derived childhood acute myeloid leukemia with biallelic FANCD1/BRCA2 disruption.
Meyer S; Fergusson WD; Whetton AD; Moreira-Leite F; Pepper SD; Miller C; Saunders EK; White DJ; Will AM; Eden T; Ikeda H; Ullmann R; Tuerkmen S; Gerlach A; Klopocki E; Tönnies H
Genes Chromosomes Cancer; 2007 Apr; 46(4):359-72. PubMed ID: 17243162
[TBL] [Abstract][Full Text] [Related]
50. Acute myeloid leukemia with t(3;21)(q26.2;q22) developing following low-dose methotrexate therapy for rheumatoid arthritis and expressing two AML1/MDS1/EVI1 fusion proteins: A case report.
Tanaka K; Oshikawa G; Akiyama H; Ishida S; Nagao T; Yamamoto M; Miura O
Oncol Lett; 2017 Jul; 14(1):97-102. PubMed ID: 28693140
[TBL] [Abstract][Full Text] [Related]
51. Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration.
Haas K; Kundi M; Sperr WR; Esterbauer H; Ludwig WD; Ratei R; Koller E; Gruener H; Sauerland C; Fonatsch C; Valent P; Wieser R
Genes Chromosomes Cancer; 2008 Apr; 47(4):288-98. PubMed ID: 18181178
[TBL] [Abstract][Full Text] [Related]
52. A novel variant of acute myelomonocytic leukemia carrying t(3;12)(q26;p13) with characteristics of 3q21q26 syndrome.
Iwase S; Furukawa Y; Horiguchi-Yamada J; Nemoto T; Takahara S; Kawano T; Sekikawa T; Ito K; Yamazaki Y; Kikuchi J; Morishita K; Yamada H
Int J Hematol; 1998 Jun; 67(4):361-8. PubMed ID: 9695409
[TBL] [Abstract][Full Text] [Related]
53. The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells.
Kurokawa M; Mitani K; Imai Y; Ogawa S; Yazaki Y; Hirai H
Blood; 1998 Dec; 92(11):4003-12. PubMed ID: 9834202
[TBL] [Abstract][Full Text] [Related]
54. Identification of a breakpoint cluster region 3' of the ribophorin I gene at 3q21 associated with the transcriptional activation of the EVI1 gene in acute myelogenous leukemias with inv(3)(q21q26).
Suzukawa K; Parganas E; Gajjar A; Abe T; Takahashi S; Tani K; Asano S; Asou H; Kamada N; Yokota J
Blood; 1994 Oct; 84(8):2681-8. PubMed ID: 7919381
[TBL] [Abstract][Full Text] [Related]
55. Breakpoint heterogeneity in (2;3)(p15-23;q26) translocations involving EVI1 in myeloid hemopathies.
De Braekeleer M; Guéganic N; Tous C; Le Bris MJ; Basinko A; Morel F; Douet-Guilbert N
Blood Cells Mol Dis; 2015 Feb; 54(2):160-3. PubMed ID: 25486926
[TBL] [Abstract][Full Text] [Related]
56. An interphase fluorescence in situ hybridisation assay for the detection of 3q26.2/EVI1 rearrangements in myeloid malignancies.
Bobadilla D; Enriquez EL; Alvarez G; Gaytan P; Smith D; Slovak ML
Br J Haematol; 2007 Mar; 136(6):806-13. PubMed ID: 17341266
[TBL] [Abstract][Full Text] [Related]
57. The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops.
Ottema S; Mulet-Lazaro R; Erpelinck-Verschueren C; van Herk S; Havermans M; Arricibita Varea A; Vermeulen M; Beverloo HB; Gröschel S; Haferlach T; Haferlach C; J Wouters B; Bindels E; Smeenk L; Delwel R
Nat Commun; 2021 Sep; 12(1):5679. PubMed ID: 34584081
[TBL] [Abstract][Full Text] [Related]
58. Identification of two critically deleted regions within chromosome segment 7q35-q36 in EVI1 deregulated myeloid leukemia cell lines.
De Weer A; Poppe B; Vergult S; Van Vlierberghe P; Petrick M; De Bock R; Benoit Y; Noens L; De Paepe A; Van Roy N; Menten B; Speleman F
PLoS One; 2010 Jan; 5(1):e8676. PubMed ID: 20084277
[TBL] [Abstract][Full Text] [Related]
59. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer.
Nanjundan M; Nakayama Y; Cheng KW; Lahad J; Liu J; Lu K; Kuo WL; Smith-McCune K; Fishman D; Gray JW; Mills GB
Cancer Res; 2007 Apr; 67(7):3074-84. PubMed ID: 17409414
[TBL] [Abstract][Full Text] [Related]
60. Retroviral insertions 90 kilobases proximal to the Evi-1 myeloid transforming gene activate transcription from the normal promoter.
Bartholomew C; Ihle JN
Mol Cell Biol; 1991 Apr; 11(4):1820-8. PubMed ID: 1848663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
